The utility of faecal calprotectin to predict post-operative recurrence in Crohńs disease

References

• Domenech E, Manosa M, Lobaton T, et al. Optimizing post-operative Crohn's disease treatment. Ann Gastroenterol. 2014;27:313–319.
   PubMedGoogle Scholar
• Connelly TM, Messaris E. Predictors of recurrence of Crohn's disease after ileocolectomy: a review. World J Gastroenterol. 2014;20:14393–14406.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856–861.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956–963.
   PubMed Web of Science ®Google Scholar
• Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13:135–142.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut. 2001;49:42–46.
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135:1123–1129.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665–672.
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Allen PB, et al. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther. 2012;35:625–633.
   PubMed Web of Science ®Google Scholar
• Brouquet A, Blanc B, Bretagnol F, et al. Surgery for intestinal Crohn's disease recurrence. Surgery. 2010;148: 936–946.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63–101.
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148:938–947e1.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease. Am J Gastroenterol. 2015; 110:865–872.
   PubMed Web of Science ®Google Scholar
• Jones J, Loftus EV, Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol. 2008;6:1218–1224.
   Google Scholar
• D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Umegae S, Kitagawa T, et al. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse. Aliment Pharmacol Ther. 2004;19:671–678.
   PubMed Web of Science ®Google Scholar
• Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197–210.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Mendall MA, et al. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573–574; author reply 4.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450–460.
   PubMed Web of Science ®Google Scholar
• D'Inca R, Dal Pont ED, Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007–2014.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009; 15:1190–1198.
   PubMed Web of Science ®Google Scholar
• Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10: 17–22.
   PubMedGoogle Scholar
• Scarpa M, D'Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum. 2007;50:861–869.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663–674.
   PubMed Web of Science ®Google Scholar
• Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010;8:591–599 e1. quiz e78-9.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: a prospective pilot study. United European Gastroenterol J. 2013;1: 368–374.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet. 1980;1:1134–1135.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512–530.
   PubMed Web of Science ®Google Scholar
• Domenech E, Manosa M, Bernal I, et al. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis. 2008;14:508–513.
   PubMed Web of Science ®Google Scholar
• Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis. 2013;7:e641–e651.
   PubMedGoogle Scholar
• Qiu Y, Mao R, Chen BL, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2015;21:315–322.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, French J, Brookes MJ, et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53–61.
   PubMed Web of Science ®Google Scholar